In a post-hoc analysis of the ADVANCE trial, cumulative SBP load was a better predictor of the occurrence of MACE in patients with T2DM compared with other BP measures.

In a meta-analysis of pooled individual participant data from 5 double-blind placebo-controlled RCTs, antihypertensive treatment was associated with a lower dementia risk compared with placebo.

AHA 2022 By participating in a mindfulness-based program, individuals with elevated office blood pressure (BP) could lower their systolic BP by 4.5 mmHg within 6 months compared with enhanced usual care.

ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.

ACC 2022 Prof. Tita shares the results of the CHAP trial, which showed that treatment of mild chronic hypertension in pregnant women to a BP goal <140/90 mmHg reduces adverse pregnancy outcomes and does not impair fetal growth.

AHA 2021 Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.

AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.

AHA 2021 Prof. Ferdinand summarizes and discusses the results from the Chinese Rural Hypertension Control (CRHC) Project.

AHA 2021 In a cluster trial of villages, BP control was significantly improved by a village doctor-led intervention for hypertension treatment compared to usual care among hypertensive residents in rural China.

This analysis of data from the EORP-AF LTG registry provides an overview of characteristics, treatment and 1-year outcomes of contemporary AF patients in the Netherlands and Belgium.

ESC 2021 The QUARTET trial showed that starting with a quarter-dose quadruple combination pill led to greater BP lowering compared to starting with standard dose monotherapy in patients with hypertension.

ESC 2021 The Salt Substitute and Stroke Study (SSaSS) showed that replacement of salt (100% NaCl) with a salt substitute (75% NaCl + 25% KCl) reduces the risk of stroke in people with prior stroke or hypertension.